RB201

RB201 is a first-in-class, oral small molecule inhibitor being developed by Rarefied Biosciences for the treatment of various autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus (lupus), inflammatory bowel disease, and psoriasis. The drug's mechanism involves targeting a key, undisclosed upstream regulator of immune activation to selectively 're-tune' misfiring immune cells. This approach is designed to restore immune balance and homeostasis while preserving the body's natural defenses against pathogens, potentially offering a safer profile compared to broad immunosuppressants. As of early 2024, RB201 has successfully completed Phase 1 human clinical trials, demonstrating its potential as a targeted therapy for chronic inflammatory diseases.